// App-Quantinova.ai

P603 : INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas

Researchers

Presenter

  • Zmora, O

Principal Investigators

  • Baumgart, D.C

  • Faubion, W

  • Ferrante, M

  • Gecse, K

  • Genestin, E

  • Geransar, P

  • Hantsbarger, G

  • Karki, C

  • Tozer, P

  • Pans, J

Medical Centers

  • Shamir Medical Center, Department of Surgery, Tel Aviv, Israel

  • University of Alberta, Gastroenterology, Edmonton, Canada

  • Mayo Clinic, Gastroenterology and Hepatology, Rochester, Minnesota, United States

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States

  • Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge MA, United States

  • St Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom

  • Hospital Clinic Universitario de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Locations

  • Israel

  • Canada

  • United States

  • Belgium

  • Switzerland

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • CX601

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved